1. Home
  2. APRE vs ALZN Comparison

APRE vs ALZN Comparison

Compare APRE & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.23

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$0.80

Market Cap

5.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
ALZN
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
APRE
ALZN
Price
$0.23
$0.80
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $3.30
N/A
AVG Volume (30 Days)
★ 133.5K
39.2K
Earning Date
11-04-2026
12-08-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
★ 76.77
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.84
52 Week High
$1.49
$2.54

Technical Indicators

Market Signals
Indicator
APRE
ALZN
Relative Strength Index (RSI) 26.17 24.65
Support Level N/A $0.84
Resistance Level $0.81 $1.29
Average True Range (ATR) 0.06 0.17
MACD -0.01 -0.04
Stochastic Oscillator 8.91 1.25

Price Performance

Historical Comparison
APRE
ALZN

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Share on Social Networks: